The global human embryonic stem cells (hESCs) market is anticipated to reach USD 1.06 billion by 2025, according to a new report by Grand View Research, Inc. Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends to be useful for tissue engineering in humans due to high histocompatibility between host and graft.
Browse the report: http://www.orbisresearch.com/reports/index/human-embryonic-stem-cells-hesc-market-analysis-by-application-regenerative-medicines-stem-cell-biology-research-tissue-engineering-toxicology-testing-by-country-u-s-uk-germany-japan-china-and-segment-forecasts-2014-2025
Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.
In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.
Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment.
Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/240830
However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques.
Further Key Findings from the Study Suggest:
hESC derivation provides a unique opportunity for early human development studies.
It is believed to hold a substantial potential for regenerative medicine and biopharma.
Differentiated derivatives of these cells are applicable for screening assays in development of novel pharmaceutical moieties.
Screening for mutagenic as well as toxic compounds can also be carried out using such derivatives.
Presence of lack of suitable donor organs and tissues for regenerative medicine is expected to increase the demand thus influencing growth.
Stem cell research is anticipated to exhibit fastest growth amongst the other applications.
However, presence of controversies pertaining to their use as a consequence of ethical considerations is responsible for steady growth.
Buy the report@http://www.orbisresearch.com/contact/purchase/240830
Europe accounts for considerable share of the market, following North America.
As per a recent survey carried out by Swiss government, citizens there are more willing to accept embryonic stem cell research than politicians.
Asia Pacific is anticipated to drive market with fastest YoY growth.
Rising awareness amongst the population and physicians with respect to associated therapies is anticipated to propel progress.
Key players contributing in this market are CellGenix GmbH, International Stem Cell Corporation, Thermo Fisher Scientific, Inc.; Kite Pharma, PromoCell GmbH, and Lonza.
Presence of clinical trial pipeline for embryonic stem cell derived therapy for targeting different diseases is expected to fuel growth.
The diseases targeted include macular degeneration, Parkinson’s disease, type I diabetes mellitus, and spinal cord injury.
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019